MARKET

CTLT

CTLT

Catalent Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

98.40
+1.71
+1.77%
Opening 10:20 05/26 EDT
OPEN
96.81
PREV CLOSE
96.69
HIGH
98.52
LOW
96.55
VOLUME
63.89K
TURNOVER
3.30M
52 WEEK HIGH
142.64
52 WEEK LOW
86.34
MARKET CAP
17.63B
P/E (TTM)
35.43
1D
5D
1M
3M
1Y
5Y
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Zacks · 2d ago
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Zacks · 2d ago
Catalent to spend $175M to expand Kentucky manufacturing site
Catalent (NYSE:CTLT) will spend $175M to expand its Winchester, Ky.-based manufacturing facility for large scale oral dose forms. In 2015, the Somerset, N.J.-based company had already doubled the site’s footprint to 190K
Seekingalpha · 6d ago
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
Zacks · 6d ago
BRIEF-Third Point Dissolves Share Stake In Accenture & Disney, Cuts Share Stake In Catalent
reuters.com · 05/16 21:27
Catalent (NYSE:CTLT) stock performs better than its underlying earnings growth over last five years
It might be of some concern to shareholders to see the Catalent, Inc. ( NYSE:CTLT ) share price down 11% in the last...
Simply Wall St. · 05/09 17:52
Europe launches first SPAC focused on production of complex drugs
reuters.com · 05/09 07:07
Morgan Stanley Maintains Overweight Rating for Catalent: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Catalent (NYSE:CTLT) and lower its price target from $145.00 to $132.00. Shares of Catalent are trading up 1.11% over the last 24 hours, at $101.06 per share. A move to $132.00 would account f...
Benzinga · 05/04 16:14
More
No Data
Learn about the latest financial forecast of CTLT. Analyze the recent business situations of Catalent Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
56.25%Buy
6.25%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTLT stock price target is 138.15 with a high estimate of 160.00 and a low estimate of 110.00.
High160.00
Average138.15
Low110.00
Current 98.40
EPS
Actual
Estimate
0.290.580.871.16
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 680
Institutional Holdings: 202.01M
% Owned: 112.72%
Shares Outstanding: 179.21M
TypeInstitutionsShares
Increased
217
12.51M
New
53
2.21M
Decreased
181
9.47M
Sold Out
75
1.10M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.49%
Pharmaceuticals & Medical Research
+0.52%
Key Executives
Chairman/Chief Executive Officer/Director
John Chiminski
President/Chief Operating Officer
Alessandro Maselli
Chief Financial Officer/Senior Vice President
Thomas Castellano
Corporate Executive
Jonathan Arnold
Corporate Executive
Karen Flynn
Corporate Executive
Aristippos Gennadios
Corporate Executive
Ricci Whitlow
Chief Human Resource Officer/Senior Vice President
Ricardo Pravda
Senior Vice President/Chief Information Officer
Charles Lickfold
Senior Vice President/General Counsel/Secretary
Steven Fasman
Senior Vice President
Michael Grippo
Senior Vice President
Scott Gunther
Senior Vice President
Kay Schmidt
Vice President
Z Mahdavi
Lead Director/Independent Director
Jack Stahl
Independent Director
Madhavan Balachandran
Independent Director
Michael Barber
Independent Director
J. Martin Carroll
Independent Director
Rolf Classon
Independent Director
Rosemary Crane
Independent Director
John Greisch
Independent Director
Christa Kreuzburg
Independent Director
Gregory Lucier
Independent Director
Donald Morel
Independent Director
Peter Zippelius
No Data
No Data
About CTLT
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

Webull offers kinds of Catalent Inc stock information, including NYSE:CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.